BNGO logo

BNGO
Bionano Genomics Inc

101,136
Mkt Cap
$11.7M
Volume
194,126.00
52W High
$6.32
52W Low
$1.06
PE Ratio
-0.07
BNGO Fundamentals
Price
$1.17
Prev Close
$1.15
Open
$1.16
50D MA
$1.54
Beta
1.70
Avg. Volume
266,190.65
EPS (Annual)
-$88.13
P/B
0.22
Rev/Employee
$307,760.00
$28.81
Loading...
Loading...
News
all
press releases
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?
Here is how Black Diamond (BDTX) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
Zacks·18d ago
News Placeholder
More News
News Placeholder
iBio, Inc. (IBIO) Reports Q1 Loss
iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +83.78% and +86.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +14.71% and +1.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock
Bionano Genomics (BNGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks·5mo ago
News Placeholder
Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Zacks·6mo ago
News Placeholder
Bionano Genomics Retail Mood Turns ‘Extremely Bearish’ Amid Revenue Guidance Shortfall
Despite a 46% gross margin improvement and significant cost cuts, the stock fell over 5% on Wednesday before jumping 20% in after-hours trading
Stocktwits·9mo ago
News Placeholder
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Zacks·9mo ago
<
...
1
>

Latest BNGO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.